Pembrolizumab
This page contains brief information about pembrolizumab (Keytruda) and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Pembrolizumab is approved to treat:
- Cervical cancer that is recurrent or metastatic. It is used in patients whose cancer has the PD-L1 protein and whose disease got worse during or after chemotherapy.¹
- Classic Hodgkin lymphoma in adults and children. It is used in patients whose disease is refractory (does not respond to treatment) or has relapsed after at least three other types of treatment.¹
- Cutaneous squamous cell carcinoma (a type of skin cancer) that is recurrent or metastatic. It is used in patients whose cancer cannot be cured by surgery or radiation therapy.
- Endometrial carcinoma that is advanced and got worse after other systemic therapies. It is used with lenvatinib in patients whose cancer is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) and cannot be treated with surgery or radiation therapy.¹
- Gastric (stomach) cancer or gastroesophageal junction cancer (a rare type of esophageal cancer) that is recurrent and either locally advanced or metastatic. It is used in patients whose cancer has the PD-L1 protein and whose disease got worse during or after two or more types of treatment including a fluoropyrimidine and platinum chemotherapy and, in some cases, HER2/neu targeted therapy.¹
- Hepatocellular carcinoma (a type of liver cancer) in patients who have been treated with sorafenib.¹
- Melanoma. It is used in:
- Patients whose cancer cannot be removed by surgery or has metastasized (spread to other parts of the body) or
- Patients who have had surgery to remove cancer that has spread to the lymph nodes.
- Merkel cell carcinoma in adults and children. It is used in patients whose disease is recurrent and either locally advanced or metastatic.¹
- Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer that is metastatic or cannot be removed by surgery. It is used to treat:
- Solid tumors in adults and children that got worse after other treatment and cannot be treated with other therapies.¹
- Colorectal cancer. It is used:
- As first-line therapy.
- In adults and children whose disease got worse after treatment with a fluoropyrimidine, oxaliplatin, and irinotecan hydrochloride.¹
MSI-H and dMMR cancers have certain genetic mutations and may not respond to some types of treatment.
- Non-small cell lung cancer. It is used:
- With pemetrexed and platinum chemotherapy as first-line treatment in patients with nonsquamous metastatic disease that does not have a mutation in the EGFR gene or ALK gene.
- With carboplatin and either paclitaxel or paclitaxel albumin-stabilized nanoparticle formulation as first-line treatment for metastatic squamous disease.
- Alone as first-line treatment in patients whose cancer has the PD-L1 protein and does not have a mutation in the EGFR gene or ALK gene. It is used in patients with stage III cancer that cannot be treated with surgery, chemotherapy, or radiation therapy. It is also used in patients with metastatic disease.
- Alone in patients whose cancer is metastatic, has the PD-L1 protein, and got worse during or after treatment with platinum chemotherapy. Patients whose cancer has EGFR or ALK gene mutations should receive pembrolizumab only if their disease got worse after treatment with an FDA-approved therapy for these mutations.
- Primary mediastinal large B-cell lymphoma. It is used in adults and children whose disease is refractory or has relapsed after at least two other therapies.¹
- Renal cell carcinoma (a type of kidney cancer) that is advanced. It is used with axitinib as first-line therapy.
- Small cell lung cancer that has metastasized. It is used in patients whose disease got worse during or after treatment with platinum chemotherapy and at least one other therapy.¹
- Solid tumors that are tumor mutational burden-high (TMB-H) and are metastatic or cannot be removed by surgery. It is used in adults and children whose disease got worse after treatment and who are not able to receive other therapies.¹
- Squamous cell carcinoma of the esophagus that is recurrent, locally advanced, or metastatic. It is used in patients whose tumors have the PD-L1 protein and whose disease got worse after treatment with systemic therapy.
- Squamous cell carcinoma of the head and neck that has metastasized or recurred (come back). It is used:
- With platinum chemotherapy and fluorouracil as first-line treatment in patients whose disease cannot be removed by surgery.
- Alone as first-line treatment in patients whose disease cannot be removed by surgery and whose tumors have the PD-L1 protein.
- Alone in patients whose disease got worse during or after treatment with platinum chemotherapy.
- Urothelial carcinoma (a type of bladder cancer). It is used in:
- Patients whose cancer is locally advanced or has metastasized and has the PD-L1 protein and cannot be treated with cisplatin.¹
- Patients whose cancer is locally advanced or has metastasized and cannot be treated with platinum chemotherapy or has gotten worse during or after treatment with platinum chemotherapy.¹
- Patients with carcinoma in situ that is high risk, does not respond to treatment with bacillus Calmette-Guérin (BCG), and has not spread to muscle. It is used in patients whose disease cannot be treated with surgery or who have decided not to have surgery.
¹This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that pembrolizumab provides a clinical benefit in these patients.
Pembrolizumab is also being studied in the treatment of other types of cancer.
More About Pembrolizumab
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Pembrolizumab - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
A New FDA Approval Furthers the Role of Genomics in Cancer Care
Pembrolizumab Approved for Some Patients with Advanced Esophageal Cancer
New Drugs, New Side Effects: Complications of Cancer Immunotherapy
Targeted Therapy–Immunotherapy Combinations Effective for Advanced Kidney Cancer
Pembrolizumab Now Second Immunotherapy Approved to Treat Merkel Cell Carcinoma
Clinical Trials Accepting Patients
Find Clinical Trials for Pembrolizumab - Check for trials from NCI's list of cancer clinical trials now accepting patients.